Publications by authors named "C L Ditto"
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.
Hematol Oncol
August 2023
Article Synopsis
- Takezaki et al. found that patients with indolent lymphomas treated with Bendamustine plus Rituximab (BR) had similar outcomes whether they received four cycles or more, suggesting that fewer cycles could be sufficient.
- In a study involving 115 CLL patients, those who received at least 4 cycles of BR had better overall response rates and progression-free survival compared to those who only received 1-3 cycles, indicating that more treatment can be beneficial.
- Current practices suggest that for fit elderly CLL patients who achieve a complete response after 4 cycles, stopping treatment may be appropriate to reduce toxicity, especially with many alternative therapies now available.
In the present analysis, we evaluated whether in elderly acute myeloid leukemia (AML) patients (>60 years), minimal residual disease (MRD) assessed by flow cytometry may have a role in guiding choice of postremission strategies. We analyzed 149 young and 61 elderly adults who achieved morphological CR after induction course of EORTC/GIMEMA protocols. Elderly patients reached a postconsolidation MRD negative status less frequently than younger ones (11 vs 28 %, p = 0.
View Article and Find Full Text PDFIn adult patients with acute lymphoblastic leukemia (ALL), Central Nervous System (CNS) involvement is associated with a very poor prognosis. The diagnostic assessment of this condition relies on the use of neuroradiology, conventional cytology (CC) and flow cytometry (FCM). Among these approaches, which is the gold standard it is still a matter of debate.
View Article and Find Full Text PDFWe assessed by flow cytometry minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) given standard-dose (SDAC) and high-dose ARA-C (HDAC) regimens. Of 163 patients enrolled, 130 (median age, 45 years; range, 18-59 years) qualified for analysis, all achieving complete remission after treatment with SDAC (n = 78) or HDAC (n = 52) plus etoposide and daunorubicin. Consolidation consisted of intermediate-dose ARA-C and daunorubicin.
View Article and Find Full Text PDF